BUY
It was upgraded today. What an earnings report, and they increased full-year guidance. Their HIV franchise continues to drive the top and bottom lines. Long-term, they continue to expand in oncolocy treatments--their pipeline looks fine.
biotechnology / pharmaceutical

Unlock the latest expert's opinion. Its free

Create a FREE account to see the latest opinions & get alerts about when to buy, sell or hold stocks

Unlock the latest opinion & get signals
BUY
Likes healthcare. This pays a 4.5% dividend yield, because of the strength of their drugs. Likes their huge pipeline of drugs, spanning cell therapy, oncology and HIV. They just beat top and bottom lines and raised their 2022 guidance.
biotechnology / pharmaceutical
premium

It’s a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
(A Top Pick Oct 27/20, Up 6.6%)Stockchase Research Editor: Michael O’Reilly Our PAST TOP PICK with GILD has triggered its stop at $64. To remain disciplined, we recommend covering the position at this time. We will look for better opportunities.
biotechnology / pharmaceutical
SELL
He sold 2 years ago. "Patience required" is a polite way of saying "sell". He got tired of the same promises. Yes it's cheap, but not executing on R&D. Report on its 20B acquisition has been delayed.
biotechnology / pharmaceutical
premium

It’s a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
(A Top Pick Oct 27/20, Up 16.7%)Stockchase Research Editor: Michael O'Reilly Our PREVIOUS TOP PICK with GILD is progressing well. To remain disciplined, we recommend trailing up the stop (from $50) to $64 at this time.
biotechnology / pharmaceutical
WEAK BUY
It is a healthcare name recently valued by investors. She likes to see a more visible pipeline in companies she buys. But this is a reasonable investment in this space.
biotechnology / pharmaceutical
BUY
They had good news about new drugs recently, but the stock still sold off. That's a sell signal.
biotechnology / pharmaceutical
SELL ON STRENGTH

It's bottoming because of interest rates. Sell it at $65. You can also swap this for Bristol-Myers.

biotechnology / pharmaceutical
WATCH
Likes the story. It has been frustrating since they like the story but the stock price has not reflected this. He thinks it is still undervalued. The core HIV franchise is stable and growing which gives good stability.
biotechnology / pharmaceutical
premium

It’s a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK
Stockchase Research Editor: Michael O'Reilly As the first developer of COVID-19 treatment with its remdesivir (approved by the FDA). The product will be sold under the name of Veklury for patients that need hospitalization. This follows recent new treatments, one for breast cancer and another for HIV. Although the drugs are expensive, they have been proven to be effective in their treatment. We would buy this with a stop-loss at $50. Yield 4.53% (Analysts’ price target is $78.65)
biotechnology / pharmaceutical
DON'T BUY
It has had a spotty history. It gained wide acknowledgement from their Hep C drug. The stock traded at an expanded multiple. The difficulty was that it was a solution and not a treatment, which means there is a terminal value. This is great for society but not for a business. They made acquisitions in the oncology department which hasn't done much since. It is an iteration for the company and not an embedded value.
biotechnology / pharmaceutical
DON'T BUY
Very disappointing. They had their hepatitis C franchise that generated high cash flow, but they poorly invested this cash. They also lead in They have remdesivir, the first Covid treatment. So, he held onto Gilead over the summer, but remdesivir didn't turn out to be the big cure. Their M&A hasn't been productive, either. They recently made a very pricey acquisition which diversifies their business, but the price they paid was too highl they really need to execute. It's a value trap. He sold his shares six weeks ago.
biotechnology / pharmaceutical
HOLD
A big healthcare company. It has recently had a tough go, but they are still positive on it. Their HIV franchise continues to expand. The new management team has a good growth strategy that he views positively. Their oncology acquisitions were good moves. The assets were not cheap so execution needs to come through.
biotechnology / pharmaceutical
premium

It's a Monthly Gems opinion which is available only for Premium members

Curated by Allan Tong since 2019.
99+ opinions with 4.15 rating.

TOP PICK
In the race to find a treatment, Gilead currently leads with its remdesivir. It's the name on every investor's lips and trading screens. Tests so far indicate that remdesivir shortens the recovery time of some Covid-19 patients, specifically those who take remdesivir recover after 11 days, which is four days faster than those who did not take it. Last week, the American FDA allowed doctors to use this drug on an emergency basis on patients hospitalized with Covid-19. However, the FDA has not formally approved remdesivir, because it requires more testing. Currently, there are several ongoing clinical trials to test whether the drug can stop Covid-19 from replicating. In other words, remdesivir helps some patients heal faster, but isn't the magic bullet, at least not yet. In this horse race, Gilead is out front, but will it cross the finish line faster. Gilead pays a 3.4% based on a payout ratio of 65.9%, and trades at a PE just under 20x, with a forward PE of 13x.
biotechnology / pharmaceutical
COMMENT
US Healthcare? Healthcare generally under-preforms in election years. A safer pick would be GILD, for their COVID-19 research and HIV drugs.
biotechnology / pharmaceutical
Showing 1 to 15 of 252 entries

Gilead Sciences Inc.(GILD-Q) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 4

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 1

Total Signals / Votes : 5

Stockchase rating for Gilead Sciences Inc. is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Gilead Sciences Inc.(GILD-Q) Frequently Asked Questions

What is Gilead Sciences Inc. stock symbol?

Gilead Sciences Inc. is a American stock, trading under the symbol GILD-Q on the NASDAQ (GILD). It is usually referred to as NASDAQ:GILD or GILD-Q

Is Gilead Sciences Inc. a buy or a sell?

In the last year, 5 stock analysts published opinions about GILD-Q. 4 analysts recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Gilead Sciences Inc..

Is Gilead Sciences Inc. a good investment or a top pick?

Gilead Sciences Inc. was recommended as a Top Pick by on . Read the latest stock experts ratings for Gilead Sciences Inc..

Why is Gilead Sciences Inc. stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Gilead Sciences Inc. worth watching?

5 stock analysts on Stockchase covered Gilead Sciences Inc. In the last year. It is a trending stock that is worth watching.

What is Gilead Sciences Inc. stock price?

On 2022-11-25, Gilead Sciences Inc. (GILD-Q) stock closed at a price of $86.26.